Integrated screening for tuberculosis and HIV in tuberculosis contact investigations: Lessons learned in North Carolina

Public Health Reports

Volumn 129, Issue SUPPL. 1, 2014, Pages 21-25

  Stout, Jason E ^a,b   Katrak, Shereen ^b   Goswami, Neela D ^b   Norton, Brianna L ^b   Fortenberry, Ellen R ^a   Foust, Evelyn ^c   Leone, Peter A ^c,d  

^a Division of Infectious Diseases and International Health ^*

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTEGRATED HEALTH CARE SYSTEM; INTERFERON GAMMA RELEASE ASSAY; MASS SCREENING; PRIORITY JOURNAL; TUBERCULOSIS; UNITED STATES; DISEASE TRANSMISSION; HEALTH PROGRAM; MORBIDITY; RISK REDUCTION; SCREENING;

EID: 84891059240     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/00333549141291s104     Document Type: Article

References (18)

1. Trends in tuberculosis-United States, 2011 [published erratum appears in MMWR Morb Mortal Wkly Rep 2012;61(18):329]. MMWR Morb Mortal Wkly Rep 2012;61(11):181-5.
2. Sprinson JE, Flood J, Fan CS, Shaw TA, Pascopella L, Young JA, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis 2003;7(12 Suppl 3):S363-8.
3. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
4. Goswami ND, Hecker EJ, Vickery C, Ahearn MA, Cox GM, Holland DP, et al. Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study. PLoS One 2012;7:e46029.
5. North Carolina Department of Health and Human Services, Communicable Disease Branch. 2011 tuberculosis statistics for North Carolina. Raleigh (NC): State of North Carolina Department of Health and Human Services, Division of Public Health; 2012. Also available from: URL: http://epi.publichealth.nc.gov/cd/tb/figures/tbannual2011.pdf [cited 2013 Jan 26].
6. North Carolina Division of Public Health. North Carolina Electronic Disease Surveillance System [cited 2012 May 28]. Available from: URL: https://ncedss.ncpublichealth.com/login.do
7. North Carolina Department of Health and Human Services, Communicable Disease Branch. North Carolina epidemiologic profile for HIV/STD prevention and care planning. Raleigh (NC): North Carolina Department of Health and Human Services, Division of Public Health; 2011. Also available from: URL: http://epi.publichealth.nc.gov/cd/stds/figures/Epi_Profile_2011.pdf [cited 2012 May 28].
8. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1-17.
9. Targeted tuberculin testing and treatment of latent tuberculosis infection. ATS/CDC Statement Committee on Latent Tuberculosis Infection membership list, June 2000. MMWR Recomm Rep 2000;49(RR-6):1-54.
10. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601.
11. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54(RR-15):1-47.
12. Li J, Marks SM, Driver CR, Diaz FA, Castro AF 3rd, de Regner AF, et al. Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: feasibility and costs. J Public Health Manag Pract 2007;13:252-62.
13. Reichler MR, Bur S, Reves R, Mangura B, Thompson V, Ford J, et al. Results of testing for human immunodeficiency virus infection among recent contacts of infectious tuberculosis cases in the United States. Int J Tuberc Lung Dis 2003;7(12 Suppl 3):S471-8.
14. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85.
15. Person AK, Goswami ND, Bissette DJ, Turner DS, Baker AV, Gadkowski LB, et al. Pairing QuantiFERON Gold In-Tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeast- ern United States. AIDS Patient Care STDS 2010;24:539-43.
16. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012;54:1259-71.
17. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011;11:247.
18. Grinsdale JA, Ho CS, Banouvong H, Kawamura LM. Programmatic impact of using QuantiFERON reg-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis 2011;15:1614-2